辛伐他汀对冠心病患者新发心房颤动预防作用.doc

辛伐他汀对冠心病患者新发心房颤动预防作用[摘要] 目的：探讨辛伐他汀对冠心病患者新发心房颤动（房颤）的预防作用。方法：选取住院治疗的冠心病患者为研究对象，将322例冠心病患者随机分为两组，辛伐他汀组（164例）给予辛伐他汀10 mg治疗，对照组（158例）给予常规治疗，观察两组患者治疗前后血清超敏C反应蛋白（hs-CRP）的变化，随访统计新发房颤发生率。结果：治疗后两组血清hs-CRP水平均较治疗前降低，辛伐他汀组降低更明显，由（6.43±1.70）mg/L降至（3.98±1.52）mg/L，两组差异有统计学意义（P＜0.05）；入选的322例患者中，54例患者发生房颤，其中，辛伐他汀组8例（4.9%），对照组46例（29%），辛伐他汀组房颤发生率明显低于对照组，两组差异有统计学意义（P＜0.05）。结论：辛伐他汀能明显降低冠心病患者房颤的发生率。 [关键词] 心房颤动；辛伐他汀；冠心病 [中图分类号] R541.4 [文献标识码]A[文章编号]1673-7210（2011）07（c）-079-02 Prevention of new occurred atrial fibrillation in coronary heart disease patients by Simvastatin ZHOU Yongping Department ofCardiology, Leshan Geriatric Hospital, Sichuan Province, Leshan 614000, China [Abstract] Objective: To evaluate the effect of Simvastatin on prevention of new occurred atrial fibrillation (AF) in coronary heart disease patients. Methods: 322 patients with coronary heart disease (CHD) were randomly divided into two groups, Simvastatin group (164 cases) was given Simvastatin 10 mg and the control group (158 cases) was given routine treatment, changes of levels of high sensitive C-reactive protein in two groups were observed before and after treatment. The incidence rates of AF were measured in following-up. Results: The level of hs-CRP decreased after treatment in two groups, Simvastatin group decreased more obvious (P＜0.05).54 cases of the 322 patients developed AF during follow-up, 8 case (4.9%) in the Simvastatin group and 46 cases (29%) in the control group, the incidence of AF in the Simvastatin group was significantly less than the control group (P＜0.05). Conclusion: Simvastatin can reduce the incidence of AF obviously in coronary heart disease patients. [Key words] Atrial fibrillation; Simvastatin; Coronary heart disease 心房颤动（房颤）是临床常见的心律失常，在冠心病患者中最容易发生，且随着年龄增长发病率逐渐增高，房颤发生导致血流动力学改变和症状恶化，心功能下降，患者生活质量下降，死亡率增加，炎症机制参与了房颤的发生发展过程，而他汀类药物广泛应用于急性冠脉综合征的治疗主要是因其抗炎机制，本研究旨在观察辛伐他汀对冠心病新发房颤的预防作用。 1资料与方法 1.1 一般资料 选取2005年6月～2010年1月我院收治的冠心病患者322例，其中，男182例，女140例，年龄46～75岁；排除标准：①年龄＞